



## Product Datasheet

<b>Product Name</b>	Noggin Human Recombinant
<b>Cata No</b>	CB500377
<b>Source</b>	<i>Escherichia Coli.</i>
<b>Synonyms</b>	SYM1, SYNS1, NOG.

### Description

The secreted polypeptide noggin, encoded by the NOG gene, binds and inactivates members of the transforming growth factor-beta (TGF-beta) superfamily signaling proteins, such as bone morphogenetic protein-4 (BMP4). By diffusing through extracellular matrices more efficiently than members of the TGF-beta superfamily, noggin may have a principal role in creating morphogenic gradients. Noggin appears to have pleiotropic effect, both early in development as well as in later stages. It was originally isolated from *Xenopus* based on its ability to restore normal dorsal-ventral body axis in embryos that had been artificially ventralized by UV treatment. The results of the mouse knockout of noggin suggest that it is involved in numerous developmental processes, such as neural tube fusion and joint formation. Recently, several dominant human NOG mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) were identified; both SYM1 and SYNS1 have multiple joint fusion as their principal feature, and map to the same region (17q22) as NOG. All NOG mutations altered evolutionarily conserved amino acid residues. The amino acid sequence of human noggin is highly homologous to that of *Xenopus*, rat and mouse.

Noggin Human Recombinant produced in *E. Coli* is a non-glycosylated, non-disulfide-linked homodimer consisting of two 206 amino acid polypeptide chains,

having a total molecular mass of approximately 46.2 kDa (each chain 23.1 kDa).

Noggin is purified by proprietary chromatographic techniques.

### Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

### Biological Activity

The ED<sub>50</sub> was determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED<sub>50</sub> for this effect is 0.05-0.08 µg/ml of Noggin.

### Purity

Greater than 95.0% as determined by SDS-PAGE.

### Formulation

Lyophilized from a 0.2µm filtered solution in 30% CH<sub>3</sub>CN, 0.1% TFA.

### Stability

Lyophilized Noggin although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Noggin should be stored at 4°C between 2-7 days and for future use below -18°C.

For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

**\* For Non-Clinical Research Use Only \***



# California Bioscience

83103 Avenue 48, Ste.1B #204

Coachella, CA 92236 USA

Phone : +1.6268339877

Email : [info@cali-bio.com](mailto:info@cali-bio.com)

**Please prevent freeze-thaw cycles.**

## Sequence

MQHYLHIRPAPSDNLPLVDLIEHPDPIFDPKEKDL  
NETLLRSLLGGH  
YDPGFMATSPPEDRPGGGGGAAGGAEDLAELD

QLLRQRPSGAMPS **Product Datasheet**

EIKGLEFSEGLAQQGKKQRLSKLRRKLMWLWS

QTFPCVLYAWNDL

GSRFWPRYVKVGSCFSKRSCSVPEGMVCKPSKS

VHLTVLRWRCQR

RGQRCGWIPIQYPIISECKCSC

**\* For Non-Clinical Research Use Only \***